Effect of eprosartan on the hemostatic system in patients with chronic kidney disease associated with hereditary thrombophilia
To study the effect of eprosartan, an angiotensin II type 1 (AT1) receptor blocker, with sympatholytic activity on the hemostatic system in patients with chronic kidney disease (CKD) associated with hereditary thrombophilia. The 12-week open-label uncontrolled trial included 31 patients with Stages...
Saved in:
Published in | Terapevtic̆eskii arhiv Vol. 85; no. 9; pp. 77 - 81 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | Russian |
Published |
Russia (Federation)
"Consilium Medicum" Publishing house
01.01.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To study the effect of eprosartan, an angiotensin II type 1 (AT1) receptor blocker, with sympatholytic activity on the hemostatic system in patients with chronic kidney disease (CKD) associated with hereditary thrombophilia.
The 12-week open-label uncontrolled trial included 31 patients with Stages I-II CKD: 15 patients with chronic glomerulonephritis and 16 with diabetic nephropathy burdening types 1 and 2 diabetes mellitus (DM) in 10 and 6 cases, respectively. In all the patients, CKD was associated with one of the heterozygous forms of thrombophilia: the polymorphic methylenetetrahydrofolate reductase gene variant C677T was found in 18 patients; the polymorphic coagulation factor V gene variant G1691A was in 9; and the polymorphic coagulation factor II gene variant G20210A in 4. Along with the thorough examination accepted in nephrology and endocrinology clinics, investigations of vascular-thrombocytic and secondary hemostasis and the anticoagulant and fibrinolytic systems were made before and after treatment.
Eprosartan therapy caused positive changes in the indicators of vascular-thrombocytic (diminished platelet aggregation, reduced surplus of von Willebrand factor and endothelin-1) and secondary (decreased coagulation factor VII activity, longer activated partial thromboplastin time) hemostasis and the anticoagulant (reduced antithrombin III deficiency) and fibrinolytic (elevated blood plasminogen concentrations) systems.
The pleiotropic effects of eprosartan may be used to correct hypercoagulability syndrome in patients with CKD associated with hereditary thrombophilia. |
---|---|
AbstractList | To study the effect of eprosartan, an angiotensin II type 1 (AT1) receptor blocker, with sympatholytic activity on the hemostatic system in patients with chronic kidney disease (CKD) associated with hereditary thrombophilia.
The 12-week open-label uncontrolled trial included 31 patients with Stages I-II CKD: 15 patients with chronic glomerulonephritis and 16 with diabetic nephropathy burdening types 1 and 2 diabetes mellitus (DM) in 10 and 6 cases, respectively. In all the patients, CKD was associated with one of the heterozygous forms of thrombophilia: the polymorphic methylenetetrahydrofolate reductase gene variant C677T was found in 18 patients; the polymorphic coagulation factor V gene variant G1691A was in 9; and the polymorphic coagulation factor II gene variant G20210A in 4. Along with the thorough examination accepted in nephrology and endocrinology clinics, investigations of vascular-thrombocytic and secondary hemostasis and the anticoagulant and fibrinolytic systems were made before and after treatment.
Eprosartan therapy caused positive changes in the indicators of vascular-thrombocytic (diminished platelet aggregation, reduced surplus of von Willebrand factor and endothelin-1) and secondary (decreased coagulation factor VII activity, longer activated partial thromboplastin time) hemostasis and the anticoagulant (reduced antithrombin III deficiency) and fibrinolytic (elevated blood plasminogen concentrations) systems.
The pleiotropic effects of eprosartan may be used to correct hypercoagulability syndrome in patients with CKD associated with hereditary thrombophilia. Aim. To study the effect of eprosartan, an angiotensin II type 1 (AT1) receptor blocker, with sympatholytic activity on the hemostatic system in patients with chronic kidney disease (CKD) associated with hereditary thrombophilia. Subjects and methods. The 12-week open-label uncontrolled trial included 31 patients with Stages I-II CKD: 15 patients with chronic glomerulonephritis and 16 with diabetic nephropathy burdening types 1 and 2 diabetes mellitus (DM) in 10 and 6 cases, respectively. In all the patients, CKD was associated with one of the heterozygous forms of thrombophilia: the polymorphic methylenetetrahydrofolate reductase gene variant C677T was found in 18 patients; the polymorphic coagulation factor V gene variant G1691A was in 9; and the polymorphic coagulation factor II gene variant G20210A in 4. Along with the thorough examination accepted in nephrology and endocrinology clinics, investigations of vascular-thrombocytic and secondary hemostasis and the anticoagulant and fibrinolytic systems were made before and after treatment. Results. Eprosartan therapy caused positive changes in the indicators of vascular-thrombocytic (diminished platelet aggregation, reduced surplus of von Willebrand factor and endothelin-1) and secondary (decreased coagulation factor VII activity, longer activated partial thromboplastin time) hemostasis and the anticoagulant (reduced antithrombin III deficiency) and fibrinolytic (elevated blood plasminogen concentrations) systems. Conclusion. The pleiotropic effects of eprosartan may be used to correct hypercoagulability syndrome in patients with CKD associated with hereditary thrombophilia. |
Author | Tkalich, L M Grankina, V Iu Sibireva, O F Zibnitskaia, L I Kaliuzhin, V V Urazova, O I Kaliuzhina, E V Sazonov, É A |
Author_xml | – sequence: 1 givenname: V V surname: Kaliuzhin fullname: Kaliuzhin, V V – sequence: 2 givenname: O F surname: Sibireva fullname: Sibireva, O F – sequence: 3 givenname: O I surname: Urazova fullname: Urazova, O I – sequence: 4 givenname: L M surname: Tkalich fullname: Tkalich, L M – sequence: 5 givenname: L I surname: Zibnitskaia fullname: Zibnitskaia, L I – sequence: 6 givenname: E V surname: Kaliuzhina fullname: Kaliuzhina, E V – sequence: 7 givenname: É A surname: Sazonov fullname: Sazonov, É A – sequence: 8 givenname: V Iu surname: Grankina fullname: Grankina, V Iu |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24261234$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kN1KAzEQhYNUbK19BckLLORvk-6llKqFgjd6vWSTiZvaTZYkIr3x2V2s9eowc4ZvZs4tmoUY4AotGCdNVXPBZmhBiCAVl5LM0SrnAyGEilpSpW7QnAkmKeNigb63zoEpODoMY4pZp6IDjgGXHnAPQ8xFF29wPuUCA_YBj1MNoWT85UuPTZ9imPwPbwOcsPUZdAasc47G6wL2PNZDAuuLTqcJnOLQxbH3R6_v0LXTxwyrP12it8ft6-a52r887TYP-8oypUrV8I67rm6EkY6IhlBpGy7NGhy1CmotuLVS1kwqWhvCmWGSNMApW9cGiLF8iXZnro360I7JD9MpbdS-_W3E9N5On3tzhFZxTYmjiijlhHaNNtQoppgDzrtp88S6P7PGz24A-0-7hMp_AFggeH8 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM DOA |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2309-5342 |
EndPage | 81 |
ExternalDocumentID | oai_doaj_org_article_73a10f17077f4af9ac1c7272fe33b016 24261234 |
Genre | Clinical Trial English Abstract Journal Article |
GroupedDBID | 123 642 ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS BCNDV CGR CUY CVF ECM EIF F5P GROUPED_DOAJ NPM SV3 |
ID | FETCH-LOGICAL-d277t-93b3fb594c6f049016d936c8ef1d7e5a43dd66526715c032c2609e31285ce0cd3 |
IEDL.DBID | DOA |
ISSN | 0040-3660 |
IngestDate | Thu Jul 04 21:07:49 EDT 2024 Thu May 23 23:18:32 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | Russian |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-d277t-93b3fb594c6f049016d936c8ef1d7e5a43dd66526715c032c2609e31285ce0cd3 |
OpenAccessLink | https://doaj.org/article/73a10f17077f4af9ac1c7272fe33b016 |
PMID | 24261234 |
PageCount | 5 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_73a10f17077f4af9ac1c7272fe33b016 pubmed_primary_24261234 |
PublicationCentury | 2000 |
PublicationDate | 2013-01-01 |
PublicationDateYYYYMMDD | 2013-01-01 |
PublicationDate_xml | – month: 01 year: 2013 text: 2013-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Russia (Federation) |
PublicationPlace_xml | – name: Russia (Federation) |
PublicationTitle | Terapevtic̆eskii arhiv |
PublicationTitleAlternate | Ter Arkh |
PublicationYear | 2013 |
Publisher | "Consilium Medicum" Publishing house |
Publisher_xml | – name: "Consilium Medicum" Publishing house |
SSID | ssj0001456177 |
Score | 1.9243547 |
Snippet | To study the effect of eprosartan, an angiotensin II type 1 (AT1) receptor blocker, with sympatholytic activity on the hemostatic system in patients with... Aim. To study the effect of eprosartan, an angiotensin II type 1 (AT1) receptor blocker, with sympatholytic activity on the hemostatic system in patients with... |
SourceID | doaj pubmed |
SourceType | Open Website Index Database |
StartPage | 77 |
SubjectTerms | Acrylates - pharmacology Adult Angiotensin II Type 2 Receptor Blockers - pharmacology chronic kidney disease eprosaptan Female Hemostasis - drug effects hereditary thrombophilia Humans Imidazoles - pharmacology Male Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - etiology Thiophenes - pharmacology Thrombophilia - complications Thrombophilia - genetics Treatment Outcome Young Adult |
Title | Effect of eprosartan on the hemostatic system in patients with chronic kidney disease associated with hereditary thrombophilia |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24261234 https://doaj.org/article/73a10f17077f4af9ac1c7272fe33b016 |
Volume | 85 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07a8MwEBYlU5fS0lf64oauppZlSfbYloZQSOjQQDajJzEldkicIUt_e_VwS-jSpYsHYyRzJ_R9dyd9h9C9g8xUqVQlmkvqAhRbJMKtrISlihtTGoqlv-A8mbLxLH-d0_leqy9_JizKA0fDPXAicGoxTzm3ubClUFj54qE1hEjHV8Lui-leMBWyK54XcP59ZI4ECcogyv-LPgYYGR2jo57_wWOc9wQdrLen6DNqCENrwbgdbeP-SjTQNuDYGSzMsvXXfmoFUXYZ6gZ6OdQN-DwqqKhwCx-1bswO-qILiN70RsfPFr4vZ92J9Q58d4SlbFc-nSLO0Gz08v48TvrGCInOOO-SkkhiJS1zxayv3GGmS8JUYSzW3FCRE60ZoxnjmKqUZMoFLaUhDoqoMqnS5BwNmrYxlwgKY6R0mF5Yr_0nVSkttlyyTDJhuVVD9OStVq2i9kXl1ajDC-ejqvdR9ZePhugi2vxnGE8MHGbmV_8x_DU6zEKTCp8YuUGDbr01t44qdPIurAr3nL5NvgA3g8FA |
link.rule.ids | 315,786,790,2115 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+eprosartan+on+the+hemostatic+system+in+patients+with+chronic+kidney+disease+associated+with+hereditary+thrombophilia&rft.jtitle=Terapevtic%CC%86eskii+arhiv&rft.au=V+V+Kaliuzhin&rft.au=O+F+Sibireva&rft.au=O+I+Urazova&rft.au=L+M+Tkalich&rft.date=2013-01-01&rft.pub=%22Consilium+Medicum%22+Publishing+house&rft.issn=0040-3660&rft.eissn=2309-5342&rft.volume=85&rft.issue=9&rft.spage=77&rft.epage=81&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_73a10f17077f4af9ac1c7272fe33b016 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0040-3660&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0040-3660&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0040-3660&client=summon |